Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Lilly buys TPOXX PRV from Siga for $80mm

Executive Summary

Siga Technologies Inc. sold its material threat medical countermeasure priority review voucher (PRV) to Eli Lilly & Co. for $80mm. Lilly did not disclose its plans for the voucher. The PRV is the first for a medical countermeasure issued by the FDA; it has previously issued vouchers for rare pediatric diseases and tropical diseases. Siga obtained the PRV in July following approval of its (TPOXX} (tecovirimat) smallpox drug.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Other

Related Companies

Advertisement
UsernamePublicRestriction

Register